-
Celastrol Rewires Mitochondrial Cholesterol in Liver Cancer
2026-09-28
A 2026 study reports that celastrol disrupts the CAV-1/SCP2 cholesterol-trafficking axis, enriching cholesterol in mitochondria and promoting mitophagy in liver cancer models. The findings connect organelle-specific cholesterol imbalance with mitochondrial stress and tumor suppression, while leaving important questions about dose, selectivity, and clinical transferability for future work.
-
DNase I (GMP-grade) for Cleaner Cas13 Assays
2026-09-27
Use DNase I (GMP-grade) as an ex vivo cleanup step to reduce DNA carryover in RNA-focused Cas13 workflows—not as a way to alter guide localization or Cas13 activity. A controlled digestion, cleanup, and no-RT check can help distinguish RNA-dependent results from DNA contamination while preserving the logic of U1- or U6-driven crRNA experiments.
-
Reparixin: Mapping CXCR1/2 Across Cell Types
2026-09-26
Reparixin is a CXCR1/2 inhibitor for investigating chemokine signaling, neutrophil behavior, and inflammatory injury. This article explains how to use receptor blockade to distinguish tumor-cell IL-8 signaling from neutrophil chemotaxis—and where the evidence does not yet connect these systems.
-
Sorafenib (BAY-43-9006) in Cancer Assays
2026-09-25
Use Sorafenib to separate tumor-cell signaling effects from VEGFR-linked angiogenesis readouts in cancer models. This workflow pairs dose-response testing with pathway and endothelial assays, while practical controls help distinguish target biology from solubility or vehicle artifacts.
-
Reparixin: Interpreting CXCR1/2 Beyond Chemotaxis
2026-09-25
Reparixin is a CXCR1/2 inhibitor commonly used to investigate neutrophil migration and inflammatory injury. This article explains how to use its receptor pharmacology to ask a different question: when does CXCL8–CXCR1 signaling support tumor-cell responses, and what controls are needed to test that link?
-
12-O-tetradecanoyl phorbol-13-acetate (TPA) Guide
2026-09-24
A practical guide to using 12-O-tetradecanoyl phorbol-13-acetate (TPA), SKU N2060, to probe PKC and ERK/MAPK signaling without mistaking pathway activation for a direct viability effect. Covers assay design, timing, handling, interpretation, and evidence-based product selection.
-
QPRT Promotes Breast Cancer Invasion via MLC Phosphorylation
2026-09-24
Liu et al. connect elevated quinolinate phosphoribosyltransferase (QPRT) with breast cancer cell migration and invasion, and identify myosin light-chain phosphorylation as a downstream correlate. Their genetic and inhibitor-based experiments implicate purinergic, Rho–ROCK, PLC, and MLCK signaling, while leaving the precise pathway order and PLC isoform-specific role open for further testing.
-
Salidroside Protects HUVECs Through EZH2 Pathways
2026-09-23
A 2024 study reports that salidroside reduces hydrogen peroxide-associated dysfunction in human umbilical vein endothelial cells, alongside changes in inflammatory and autophagy-related proteins. Molecular docking and EZH2 knockdown support EZH2 as a candidate mediator, while the in-vitro findings leave direct target engagement and autophagic flux for further testing.
-
N3-kethoxal Workflows for RNA and DNA Mapping
2026-09-23
N3-kethoxal combines membrane permeability, selective guanine reactivity, and an azide handle for mapping nucleic-acid accessibility in purified samples or living cells. This guide translates the probe into practical workflows for RNA structure probing, accessible-DNA analysis, and RNA–protein interaction studies, with controls and troubleshooting built in.
-
Sunitinib: From RTK Blockade to Ferroptosis
2026-09-22
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor widely used to study angiogenesis, tumor signaling, and cancer-cell death. This guide connects its established RTK pharmacology with TRIB3-dependent ferroptosis and provides a practical framework for distinguishing apoptosis, cell-cycle arrest, and ferroptotic responses in renal cell carcinoma models.
-
MRSA EVs Drive OSCC via IL-8–CXCR1 Signaling
2026-09-22
This 2026 study identifies methicillin-resistant Staphylococcus aureus extracellular vesicles as active drivers of oral squamous cell carcinoma growth, rather than passive by-products of infection. Its MRSA-versus-MSSA comparison, pathway analysis, genetic validation, and mouse experiments define an ERK/c-Jun–IL-8–CXCR1 signaling relay that connects antibiotic-resistant bacteria with tumor-cell proliferation.
-
Reparixin: CXCR1/2 Signaling in Inflammation
2026-09-21
Reparixin is a CXCR1/2 inhibitor for separating chemokine-receptor signaling from upstream inflammatory or tumor-derived stimuli. This article translates recent MRSA extracellular-vesicle findings into a rigorous framework for neutrophil assays, tissue-injury models, and carefully bounded cancer research applications.
-
Cy3 TSA Fluorescence System Kit for FASN Studies
2026-09-21
Translate the p53-R280K/SREBP1/FASN mechanism into sensitive spatial assays with a practical Cy3 TSA workflow for IHC, ICC, and ISH. This TSA fluorescence kit is especially useful when conventional fluorescence microscopy detection struggles with weak targets in fixed cells or tissue.
-
HA Tag Peptide for Exosome Mechanism Studies
2026-09-20
The Influenza Hemagglutinin (HA) Peptide provides a selective route for detecting, isolating, and eluting HA-tagged proteins in trafficking studies. This article connects competitive HA affinity workflows with the RAB31-controlled exosome pathway and explains how tag-based assay design can separate cargo abundance from vesicle fate.
-
Norepinephrine Bitartrate: Formulation-Smart Research
2026-09-19
Norepinephrine bitartrate is more than a potent adrenergic agonist: its salt form can influence how cardiovascular experiments are designed, normalized, and reported. This formulation-aware guide connects receptor pharmacology with reproducible cardiomyopathy and signaling research.